MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors

Key facts

Study ID

NCT02503774

Run by

MedImmune LLC

People needed

192

Starts

2015-07-24

Expected to finish

2023-03-07

Last updated by the study team

2023-07-11

Who can join

Age: 18 and older, up to 101. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants; age ≥ 18
• Written and signed informed consent must be obtained
• Have histologic or cytologic documentation of solid tumor including EGFRm NSCLC
• Participants must have at least 1 lesion that is measurable using RECIST guidelines
• Participants must consent to provide archived tumor specimens or tumor biopsies for correlative biomarker studies.
• Eastern Cooperative Oncology Group performance score of 0 or 1
• Adequate organ function

You may not qualify if…

• Prior treatment with tumor necrosis factor receptor superfamily agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, PD-L1, and anti PD-L1.
• Participants who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions
• Cardiac or peripheral vascular disease meeting any of the following criteria:
• Past history of myocardial infarction in the prior 12 months
• Past history of stroke or transient ischemic attack requiring medical therapy
• Congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification
• Grade 3 or greater edema (eg, peripheral, pulmonary)
• History of Grade 3 or greater thromboembolic events in the prior 12 months
• Participants with active tuberculosis are ineligible. In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be ruled out
• Active or prior documented autoimmune or inflammatory disorders
• Untreated central nervous system (CNS) metastatic disease
• Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
• Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active peptic ulcer disease or gastritis, uncontrolled hypertension, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirement

Where it is running

• Research Site — La Jolla, California, United States
• Research Site — New Haven, Connecticut, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Dallas, Texas, United States
• Research Site — Houston, Texas, United States
• Research Site — Camperdown, Australia
• Research Site — Parkville, Australia
• Research Site — St Leonards, Australia
• Research Site — Woolloongabba, Australia
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.